Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Omeros Corp (NASDAQ:OMER)

11.76
Delayed Data
As of Jul 29
 +0.06 / +0.51%
Today’s Change
8.90
Today|||52-Week Range
30.23
-25.24%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$437.9M

Company Description

Omeros Corp. engages in the development and commercialization of small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. Its products are derived from its proprietary PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological, and other surgical and medical procedures. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Contact Information

Omeros Corp.
201 Elliott Avenue West
Seattle Washington 98119
P:(206) 676-5000
Investor Relations:

Employees

Shareholders

Individual stakeholders7.78%
Other institutional41.31%
Mutual fund holders15.51%

Top Executives

Gregory A. DemopulosChairman, President & Chief Executive Officer
David R. TollSenior Director-Finance
Michael A. JacobsenCFO, Treasurer, Chief Accounting Officer & VP
George A. GaitanarisChief Scientific Officer & Vice President
J. Steven WhitakerChief Medical Officer & VP-Clinical Development